COX Cox Comm CL A SC23

Nicox launches Sjö(TM) in the US and partners with the Sjögren's Syndrome
Foundation

..................................

  * Nicox launches Sjö(TM), an advanced diagnostic for early detection of
    Sjögren's Syndrome, a serious, progressive and underdiagnosed autoimmune
    disease

  * US eye care professionals are uniquely positioned to identify Sjögren's
    Syndrome as dry eye is a common early symptom


Nicox S.A. (NYSE Euronext Paris: COX) today announces that Sjö(TM), an advanced
diagnostic panel for the early detection of Sjögren's Syndrome, has been
launched in the US. Nicox's sales force is now promoting Sjö(TM) in select US
markets to eye care professionals, who are in a unique position to identify
Sjögren's Syndrome as dry eye is a significant and early symptom of the
condition. Nicox also announces that it has formed a partnership with the
Sjögren's Syndrome Foundation to raise awareness of the disease among eye care
professionals.

Jerry St. Peter, Executive Vice President and General Manager of Nicox Inc,
commented, "The launch of a proprietary, novel test for early detection of
Sjögren's Syndrome demonstrates the potential of ophthalmic diagnostics in a
wide range of conditions. Sjö(TM) is the second diagnostic which Nicox has
launched in the US and represents another important step towards our goal of
becoming a leading provider of ophthalmic diagnostics, drugs and devices. We are
pleased to partner with the Sjögren's Syndrome Foundation to increase awareness
of this serious and underdiagnosed condition among eye care practitioners across
the country."

Introducing Sjö(TM) for the early detection of Sjögren's Syndrome

Sjö(TM) is an advanced diagnostic panel for the detection of Sjögren's Syndrome,
with high sensitivity and specificity. Sjögren's Syndrome is among the most
common and underdiagnosed autoimmune diseases which can lead to significant
morbidity, diminished gland performance and atrophy.  It is estimated to affect
4 million people in the US, of which 3 million are undiagnosed[1],[2].

Sjö(TM) is a proprietary laboratory test developed by Immco Diagnostics Inc.
which combines traditional markers with three novel, proprietary biomarkers,
allowing earlier detection of the disease. It will be promoted to US eye care
professionals by Nicox's US sales force under an exclusive North American
agreement signed with Immco in June 2013. Sjö(TM) is the second product launched
by Nicox in the US following the launch of AdenoPlus®, a rapid point-of-care
diagnostic test that aids in the differential diagnosis of acute conjunctivitis,
in October 2012. Over the past year, Nicox has been building its own specialist
sales force in selected US markets to support these and other future launches.

Early Diagnosis Can Improve Management of Sjögren's Syndrome

Sjögren's Syndrome causes patients' immune cells to attack moisture-producing
glands resulting in dry eye, which is one of the early and hallmark symptoms of
the disease. Many Sjögren's patients first see their eye care practitioner with
dry eye symptoms which are often mistaken for routine dry eye. It is estimated
that more than 20 million patients aged 40 years and older suffer from dry eyes
in the US[3], and as many as 1 in 10 dry eye patients may also have Sjögren's
Syndrome[4].

Eye care practitioners are therefore in a unique position to help identify
patients with Sjögren's Syndrome. Currently, there is an average delay of 4.7
years for patients to receive an accurate diagnosis, and patients are often
diagnosed in late stages of the disease after gland degradation has taken
effect. Earlier detection is important to allow time for proper management and
to help avoid further complications.

Sjö(TM) was approved by US regulatory authorities in 2013 and is available to
eye care practitioners across North America (US, Canada, Puerto Rico, Mexico).
The simple, in-office test can be easily incorporated into every dry eye
screening. US eye care practitioners can obtain more information and order
Sjö(TM) by calling +1.855.MY.NICOX (+1.855.696.4269). Sjö(TM) is not available
in Europe for the time being.

Nicox forms partnership with the US Sjögren's Syndrome Foundation

Nicox has established a partnership with the US Sjögren's Syndrome Foundation to
raise awareness of the prevalence, seriousness and significance of Sjögren's
Syndrome to eye care specialists. A targeted media campaign over the next few
months will aim to educate specialists about the disease and the role they can
play in early detection.

"The Sjögren's Syndrome Foundation is honored to be partnering with Nicox as
they unveil their new Sjögren's diagnostic," commented Steven Taylor, Chief
Executive Officer at the Sjögren's Syndrome Foundation. "This partnership will
help educate eye care professionals about the seriousness of Sjögren's and
encourage them to identify potential Sjögren's patients, enabling them to
receive proper diagnosis and timely medical care to treat this serious
autoimmune disease."

Exclusive North American Agreement with Immco Diagnostics Inc.

The agreement with Immco grants Nicox exclusive rights to promote Sjö(TM) to eye
care practitioners in North America (US, Canada, Puerto Rico, Mexico). Nicox
will be responsible for all marketing activities, while Immco will carry out the
test in its CLIA-approved laboratory in Buffalo, NY, and be responsible for
regulatory activities and reimbursement. Nicox will receive a majority share of
revenue generated from eye care practitioners and no upfront or milestones
payments will be made by Nicox.

Nicox also has an option to negotiate an agreement to promote the test in the
rest of the world. Immco and Nicox are evaluating the feasibility and
implementation steps for the test in other markets, including Europe.

About Sjögren's Syndrome

Sjögren's Syndrome is a systemic chronic autoimmune disorder of the exocrine
glands with associated lymphocytic infiltrates in affected glands. Involvement
of the lacrimal and salivary glands leads to the classic symptoms of dryness of
the eyes and mouth.

Ocular signs and symptoms of Sjögren's Syndrome are consistent with the
presentation of dry eye syndrome. Patients often complain of ocular irritation
with the accompanying symptoms: burning, stinging, itching, foreign body
sensation, lid irritation and swelling, photophobia, ocular fatigue, mucoid
discharge.  As disease progression advances, patients experience significant
morbidity, diminished gland performance, and eventual atrophy.

Damage to other body parts (joints, thyroid, kidneys, liver etc.), and increased
dental damage (tooth loss, infection) is also common in advanced disease, along
with an increased risk of developing lymphoma.

Sjögren's symptoms frequently overlap with or "mimic" those of other diseases
including lupus, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome,
and multiple sclerosis. Dryness can also occur for other reasons, such as a side
effect of medications such as anti-depressants and high blood pressure
medication. There is no single test that will confirm diagnosis. Rheumatologists
have primary responsibility for diagnosing and managing Sjögren's and can
conduct a series of tests and ask about symptoms. An international group of
experts formulated classification criteria for Sjögren's which help doctors
arrive at a diagnosis. These criteria consider dryness symptoms, changes in
salivary (mouth) and lacrimal (eye) gland function, and systemic (whole body)
findings[1].

About the US Sjögren's Syndrome Foundation

The Sjögren's Syndrome Foundation is a United States non-profit organization
focused on increasing research, education and awareness for Sjögren's Syndrome.
It was founded in 1983 to help Sjögren's patients cope with their disease,
increase awareness, and support research efforts. The United States Sjögren's
Syndrome Foundation serves as the lead organization for all other Sjögren's
groups, worldwide. For more information, please visit www.sjogrens.org.

...................................

References:

[1] Sjögren's Syndrome Foundation. 2001. Available at http://www.sjogrens.org.
Accessed September 5, 2013.

[2] Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of
Sjögren's Syndrome. Arch Intern Med. 2004;164: 1275-1284.

[3] 2010 Datamonitor report.

[4] Liew M, Zhang M, Kim E, et al. Prevalence and predictors of Sjögren's
syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br
J Ophthalmol. 2012;96: 1498-1503.

...................................

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company
focused  on the ophthalmic  market. With a  heritage of innovative R&D, business
development  and commercial expertise, the Nicox  team is building a diversified
portfolio  of therapies  and diagnostic  tools that  can help  people to enhance
their  sight. The Company's commercial  portfolio and near-term pipeline already
include several innovative diagnostic tests intended for eye care professionals,
as  well  as  a  range  of  eye  care products. Nicox's key proprietary asset in
ophthalmology  is  latanoprostene  bunod,  a  novel  compound  based  on Nicox's
proprietary  nitric  oxide  (NO)-donating  R&D  platform,  currently in Phase 3
clinical  development  in  collaboration  with  Bausch  + Lomb for the potential
treatment  of  glaucoma  and  ocular  hypertension.  Further NO-donors are under
development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing
commercial infrastructure in North America and in the major European markets and
an  expanding international presence  through partners. Nicox  S.A. is listed on
Euronext  Paris (Compartment B: Mid Caps). For  more information on Nicox or its
products please visit www.nicox.com.


..................................

This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated in
the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are
presented in the 4th chapter of the « Document de référence, rapport financier
annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés
Financiers (AMF) on March 22, 2013 and available on Nicox's website
(www.nicox.com) and on the AMF's website (www.amf-france.org).

...................................

 Nicox Contact   Gavin Spencer | Executive Vice President Corporate Development

                 Tel +33 (0)4 97 24 53 00 | communications@nicox.com

 Media Relations



 Europe          FTI Consulting

                 Julia Phillips | D+44 (0)20 7269 7187 | M +44 (0) 7770 827 263

                 Julia.Phillips@fticonsulting.com

                 Stephanie Cuthbert | D +44 (0)20 3077 0458 | M +44 (0)
                 7843 080947

                 Stephanie.Cuthbert@fticonsulting.com

                 Mo Noonan | D +44 (0)20 7269 7116 | M +44 (0)7876 444 977

                 Mo.Noonan@fticonsulting.com

 United States   Pascale Communications

                 Amy Phillips | M +1 412 327 9499

                 Amy@pascalecommunications.com



Nicox S.A.
Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia Antipolis |
06560 Valbonne | France
T: +33 (0)4 97 24 53 00   |   F: +33 (0)4 97 24 53 99

www.nicox.com


Nicox launches Sjö(TM) in the US and partners with the Sjögren's Syndr: http://hugin.info/143509/R/1742281/585663.pdf

[HUG#1742281]

Cox Communications (NYSE:COX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024

Cox Communications (NYSE:COX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024